Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose vs Conventional-Dose Oral Isotretinoin in Acne Vulgaris
NCT07639073Phase 4Not yet recruiting
- Sponsor
- Pakistan Institute of Medical Sciences
- Start
- Jul 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 4, randomised trial of isotretinoin in acne vulgaris (2 arms), sponsored by Pakistan Institute of Medical Sciences. Primary endpoints: Global Acne Grading System at 12 weeks and Total acne lesion count at 12 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
isotretinoin
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT07639073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07639073.